Updated:
Cytek Biosciences
Cytek Biosciences is a company specializing in cell analysis solutions for the biomedical research sector. It offers flow cytometry systems, reagents, and...
Cytek Biosciences
Cytek Biosciences is a company specializing in cell analysis solutions for the biomedical research sector. It offers flow cytometry systems, reagents, and software for studying immune cells. Cytek's products are used in research areas such as immuno-oncology, infectious diseases, and drug discovery.
General information
Firm type
Medical Devices / Biotechnology
Year founded
2014
Location
Region
North America
Country
United States
City
Fremont
Corporate office
Fremont, CA, United States
Additional offices
Shanghai, China
Principals
Wenbin Jiang
CEO
Ming Yan
CFO
Sector focus
Frequently asked questions
Who runs investment decisions at Cytek Biosciences?
Wenbin Jiang is CEO and founder. The company is publicly traded, so investment decisions are governed by a board of directors, not a centralized family office. Jiang and the executive team drive strategic and capital-allocation decisions.
How does Cytek Biosciences source proprietary deal flow?
Cytek is a technology company, not an investment firm. Its growth comes from internal R&D, licensing agreements, and targeted acquisitions—such as the 2023 purchase of Levitas Bio's flow cytometry assets. The firm does not operate a separate venture arm.
Is Cytek Biosciences structured as a single family office or does it operate more like a venture firm?
Neither. Cytek is a publicly traded biotechnology company (ticker: CTKB on Nasdaq). It is not a family office or venture firm. It was founded by an entrepreneur and backed by venture investors such as Warburg Pincus.
What investment stages does Cytek Biosciences typically target?
Cytek does not make external investments. Its capital activities focus on internal product development and occasional bolt-on acquisitions of complementary technologies or IP.
Which sectors does Cytek Biosciences explicitly avoid?
The company focuses exclusively on life science tools, specifically flow cytometry and cell analysis. It does not participate in any other investment sectors or asset classes.
How is Cytek Biosciences related to its parent or related vehicles?
Cytek is an independent public company. Its largest institutional shareholders include Warburg Pincus and other venture investors. There is no family office or single controlling shareholder.
Where does the underlying wealth of Cytek Biosciences come from?
Cytek Biosciences is a corporation, not a family office. Its capital comes from public equity markets and institutional investors. The founder Wenbin Jiang's wealth derives from his equity stake in the company.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on investors?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: